665 related articles for article (PubMed ID: 30644983)
21. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.
van Laar JM; Farge D; Sont JK; Naraghi K; Marjanovic Z; Larghero J; Schuerwegh AJ; Marijt EW; Vonk MC; Schattenberg AV; Matucci-Cerinic M; Voskuyl AE; van de Loosdrecht AA; Daikeler T; Kötter I; Schmalzing M; Martin T; Lioure B; Weiner SM; Kreuter A; Deligny C; Durand JM; Emery P; Machold KP; Sarrot-Reynauld F; Warnatz K; Adoue DF; Constans J; Tony HP; Del Papa N; Fassas A; Himsel A; Launay D; Lo Monaco A; Philippe P; Quéré I; Rich É; Westhovens R; Griffiths B; Saccardi R; van den Hoogen FH; Fibbe WE; Socié G; Gratwohl A; Tyndall A;
JAMA; 2014 Jun; 311(24):2490-8. PubMed ID: 25058083
[TBL] [Abstract][Full Text] [Related]
22. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica.
Burt RK; Balabanov R; Han X; Burns C; Gastala J; Jovanovic B; Helenowski I; Jitprapaikulsan J; Fryer JP; Pittock SJ
Neurology; 2019 Oct; 93(18):e1732-e1741. PubMed ID: 31578302
[TBL] [Abstract][Full Text] [Related]
23. Survival, and time to an advanced disease state or progression, of untreated patients with moderately severe multiple sclerosis in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation.
Daumer M; Griffith LM; Meister W; Nash RA; Wolinsky JS
Mult Scler; 2006 Apr; 12(2):174-9. PubMed ID: 16629420
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of autologous hematopoietic stem-cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis.
Mariottini A; Innocenti C; Forci B; Magnani E; Mechi C; Barilaro A; Nistri R; Fani A; Saccardi R; Massacesi L; Repice AM
Eur J Neurol; 2019 Apr; 26(4):624-630. PubMed ID: 30414315
[TBL] [Abstract][Full Text] [Related]
25. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
[TBL] [Abstract][Full Text] [Related]
26. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
27. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
[TBL] [Abstract][Full Text] [Related]
28. A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature.
Das J; Gill A; Lo C; Chan-Lam N; Price S; Wharton SB; Jessop H; Sharrack B; Snowden JA
Front Immunol; 2020; 11():668. PubMed ID: 32431694
[TBL] [Abstract][Full Text] [Related]
29. Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway.
Kvistad CE; Lehmann AK; Kvistad SAS; Holmøy T; Lorentzen ÅR; Trovik LH; Kristoffersen EK; Bø L; Torkildsen Ø
Mult Scler; 2024 May; 30(6):751-754. PubMed ID: 38345003
[TBL] [Abstract][Full Text] [Related]
30. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
[TBL] [Abstract][Full Text] [Related]
31. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
[TBL] [Abstract][Full Text] [Related]
32. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
[TBL] [Abstract][Full Text] [Related]
33. Autologous stem cell transplant in adult multiple sclerosis patients: A study from North India.
Dayama A; Bhargava R; Kurmi SR; Jain S; Dua V
Neurol India; 2020; 68(2):454-457. PubMed ID: 32415023
[TBL] [Abstract][Full Text] [Related]
34. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
35. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus.
Burt RK; Traynor A; Statkute L; Barr WG; Rosa R; Schroeder J; Verda L; Krosnjar N; Quigley K; Yaung K; Villa Bs M; Takahashi M; Jovanovic B; Oyama Y
JAMA; 2006 Feb; 295(5):527-35. PubMed ID: 16449618
[TBL] [Abstract][Full Text] [Related]
36. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
[TBL] [Abstract][Full Text] [Related]
37. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
Muraro PA; Pasquini M; Atkins HL; Bowen JD; Farge D; Fassas A; Freedman MS; Georges GE; Gualandi F; Hamerschlak N; Havrdova E; Kimiskidis VK; Kozak T; Mancardi GL; Massacesi L; Moraes DA; Nash RA; Pavletic S; Ouyang J; Rovira M; Saiz A; Simoes B; Trnený M; Zhu L; Badoglio M; Zhong X; Sormani MP; Saccardi R;
JAMA Neurol; 2017 Apr; 74(4):459-469. PubMed ID: 28241268
[TBL] [Abstract][Full Text] [Related]
38. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up more than 10 years after HSCT: a monocentric experience.
Frau J; Carai M; Coghe G; Fenu G; Lorefice L; La Nasa G; Mamusa E; Vacca A; Marrosu MG; Cocco E
J Neurol; 2018 Feb; 265(2):410-416. PubMed ID: 29270686
[TBL] [Abstract][Full Text] [Related]
40. Feasibility study to assess lesion repair in relapsing-remitting multiple sclerosis: A randomized controlled pilot clinical trial of domperidone add-on treatment.
Zhang Y; Liu WQ; Hosseinpour Z; Pike GB; Cerchiaro G; Greenfield J; Yong VW; Metz LM
Mult Scler Relat Disord; 2024 May; 85():105525. PubMed ID: 38461731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
